58 completed, 15 unknown, 6 not yet recruiting, 6 recruiting. 30 Phase 2, 22 Phase 4, 20 Phase 3, 13 Not applicable, 11 Phase 1.
Follow Febuxostat: new trials by email Literature Review of Febuxostat trials Research Report on Febuxostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Boosting Osimertinib Blood Brain Barrier Penetration Osimertinib & febuxostat - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Maastricht University Medical Center | 7 | 2026-06-01 | 2026-06-05 |
| Comparison of the Effect of Allopurinol Versus Febuxostat on Serum Uric Acid in Patients With Chronic Kidney Disease Associated With Hyperuricemia Febuxostat, allopurinol - Hyperuricemia, Renal Insufficiency, Chronic | Not applicable | Active not recruiting | Nishtar Medical University | 66 | 2026-05-13 | 2026-09-30 |
| Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia BR2251, Febuxostat - Gout and Hyperuricemia | Phase 2 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 160 | 2026-04-01 | 2026-03-27 |
| Tigulixostat (IBI128) vs Febuxostat in Gout Febuxostat, Tigulixostat - Gout | Phase 3 | Active not recruiting | Innovent Biologics Technology Limited (Shanghai R&D Center) | 600 | 2026-03-17 | 2026-09-01 |
| The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia SHR4640 ï¼›Febuxostat, SHR4640 ; Febuxostat, SHR4640 - Primary Gout and Hyperuricemia | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 340 | 2026-02-09 | 2026-04-07 |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT Orlistat 120 mg, Allopurinol 100 up to 600mg/day, Febuxostat 40mg Tab - Gout, Obesity | Not applicable | Not yet recruiting | XueMei Guo | 120 | 2025-12-10 | 2026-01-08 |
| Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients Febuxostat 40 mg, Standard medical treatment - Intracranial Hemorrhage | Phase 2 | Recruiting | Tanta University | 46 | 2025-11-20 | 2026-07-15 |
| Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects Amiodarone Hydrochloride Tablets, Febuxostat Tablets - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 1 | Not yet recruiting | Jemincare | 48 | 2025-10-30 | 2025-09-18 |
| the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More Febuxostat - Gout, Uric Acid | Phase 4 | Recruiting | Seoul National University Hospital | 59 | 2025-09-10 | 2026-04-29 |
| A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease Febuxostat, Inosine - Parkinson's Disease (PD) | Phase 1 | Recruiting | Fujita Health University | 24 | 2025-06-27 | 2025-09-12 |
| Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients Febuxostat Tablets, Metformin - Gout | Phase 2 | Completed | Mostafa Bahaa | 60 | 2025-05-30 | 2026-09-17 |
| Effect of Dotinurad in Hyperuricemia With Hypertension Dotinurad, Febuxostat - Hyperuricemia or Gout, Hypertension | Phase 4 | Recruiting | Saga University | 360 | 2025-03-28 | 2025-12-15 |
| Study on the Efficacy and Safety of Thermotherapy in the Treatment of Refractory Gout Hyperthermia combined with oral febuxostat., Febuxostat - Refractory Gout | Not applicable | Not yet recruiting | The First Hospital of Jilin University | 128 | 2024-11-01 | 2024-10-22 |
| Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine Febuxostat, Mesalamine - Ulcerative Colitis | Early Phase 1 | Not yet recruiting | Tanta University | 46 | 2024-09-01 | 2024-07-29 |
| A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects Febuxostat, IBI128 - Gout, Hyperuricemia | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 84 | 2024-07-10 | 2025-03-27 |
| Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults HR091506 tablets + placebo of febuxostat tablets, febuxostat tablets + placebo of HR091506 tablets - Gout With Hyperuricemia in Adults | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 434 | 2024-06-01 | 2024-05-16 |
| Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media Thickness Febuxostat 40 mg - Carotid Intima- Media Thickness | Phase 1 | Completed | Ain Shams University | 50 | 2024-05-24 | 2026-07-29 |
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 636 | 2024-04-22 | 2024-09-19 |
| Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults HR091506 tablets + placebo of febuxostat tablets, febuxostat tablets + placebo of HR091506 tablets - Gout With Hyperuricemia in Adults | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 765 | 2023-12-14 | 2025-10-02 |
Showing 20 of 94. Sign in to see all of them.
Gout (45) · Hyperuricemia (35) · Renal Insufficiency, Chronic (7) · Hypertension (5) · Cardiovascular Diseases (3) · Arthritis, Gouty (2) · Coronary Artery Disease (2) · Diabetes Mellitus (2) · Diabetic Nephropathies (2) · Inflammation (2) · Non-alcoholic Fatty Liver Disease (2) · Tumor Lysis Syndrome (2) · Adenine phosphoribosyltransferase deficiency (1) · Albuminuria (1) · Angina Pectoris (1)
Takeda (15) · Jiangsu HengRui Medicine Co., Ltd. (6) · Ain Shams University (4) · Ardea Biosciences, Inc. (4) · AstraZeneca (3) · Tanta University (3) · Arthrosi Therapeutics (2) · Gilead Sciences (2) · Menarini Group (2) · Seoul National University Hospital (2) · Shanghai 10th People's Hospital (2) · TWi Biotechnology, Inc. (2) · Ai Peng (1) · Assiut University (1) · Astellas Pharma Taiwan, Inc. (1)
United States (27) · China (16) · Egypt (6) · Japan (6) · Taiwan (5) · Canada (4) · Poland (4) · Australia (3) · New Zealand (3) · South Korea (3) · Hungary (2) · Italy (2) · Mexico (2) · Netherlands (2) · Pakistan (2)
Ai Peng, MD, PhD (1) · Ai Peng, Ph.D., M.D. (1) · Alexandra Steinberg, MD, PhD (1) · Amber S Holdiness, PharmD (1) · Angela Capriati, MD, PhD (1) · Bin Liu, M.D. (1) · Chang-Youh Tsai (1) · Cheng-Wei Liu, M.D. (1) · Chris Storgard, MD (1) · Christopher Wynne, MBChB, Grad Dip Pharm Med (1) · Claudio Borghi, Prof (1) · Daniel O'Connor, UCSD (1) · David ZI Cherney, MD, PhD (1)
PMID 21353107, PMID 22052584, PMID 32951150, PMID 16911575, PMID 18600509, PMID 12421831, PMID 15698861, PMID 15751090, PMID 16339094, PMID 17053334, PMID 18349746, PMID 18975369, PMID 19141576, PMID 19286847, PMID 20370912, PMID 21169856, PMID 21572152, PMID 21849262, PMID 22132950, PMID 22316106, PMID 22436129, PMID 22795277, PMID 23683134, PMID 23929928, PMID 26013187, PMID 26216382, PMID 26724837, PMID 26894653, PMID 27005768, PMID 27980008, PMID 28270924, PMID 28408434, PMID 28597604, PMID 28975718, PMID 29102979, PMID 29447788, PMID 29527974, PMID 29657831, PMID 29848361, PMID 29868853, PMID 30073793, PMID 30085130, PMID 30616614, PMID 30631120, PMID 30837873, PMID 30844048, PMID 31752638, PMID 31870173, PMID 32871874, PMID 32877573
2014 (1), 2016 (1), 2025 (1), U54DK083908 (1)